The American Journal of Managed Care

New LAMA/LABA FDC Inhaler May Be Better Option for COPD Patients

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...
Monthly Prescribing Reference

Does Adding LABA/ICS to Tiotropium Improve COPD Outcomes?

Due to lack of power, the results did not allow for a conclusion to be drawn. Overall, moderate-quality evidence indicated that tiotropium + LABA/ICS vs. tiotropium + placebo decreased hospital ...
Nature

Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study

When standard doses of inhaled corticosteroids (ICS) fail to control symptoms in children aged >4 years, guidelines recommend the addition of a long-acting β 2-agonist (LABA), with other treatment ...
Healio

LAMA/LABA therapy reduced risk for COPD exacerbation, pneumonia hospitalization

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
The American Journal of Managed Care

Initial Maintenance Therapy Adherence Among Older Adults With Asthma-COPD Overlap

Older adults with coexisting asthma and chronic obstructive pulmonary disease (COPD), known as asthma-COPD overlap, who take fixed-dose combinations of inhaled corticosteroids and long-acting β ...
Nature

The frequency of, and adherence to, single maintenance and reliever therapy instructions in asthma: a descriptive analysis

Inhaled corticosteroid/long-acting β 2-agonist (ICS/LABA) fixed-dose combinations are recommended regular maintenance options for asthma. ICS/LABAs containing ...
Business Wire

US FDA Updates SYMBICORT Label with LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...
Monthly Prescribing Reference

Triple Therapy for Symptomatic Asthma in Patients Receiving ICS/LABA

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...
Medscape

Long-Acting Muscarinic Antagonist Therapy Takes a Hit in GINA Update

In keeping with the new trend for providing "living guidelines," the Global Initiative for Asthma (GINA) Scientific Committee released their latest update a few months ago. The push toward earlier ...
Medscape

What Bronchodilator Options Do We Have for COPD?

Chronic obstructive pulmonary disease (COPD) is common and can be highly symptomatic. Other than smoking cessation, we have no therapies that have been clearly shown to improve survival. Several ...
FierceBiotech

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and ...

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response The ...